<DOC>
	<DOCNO>NCT00577148</DOCNO>
	<brief_summary>The purpose study assess effect rimonabant treatment histological feature Nonalcoholic Steatohepatitis ( NASH ) patient Type 2 diabetes .</brief_summary>
	<brief_title>An Efficacy Safety Study Rimonabant Treatment Nonalcoholic Steatohepatitis ( NASH ) Patients With Type 2 Diabetes</brief_title>
	<detailed_description>The total duration per patient approximately 22 month include 18-month double-blind treatment period .</detailed_description>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Rimonabant</mesh_term>
	<criteria>Patients Type 2 diabetes mellitus diagnosis NASH Excessive alcohol use Presence Type 1 diabetes mellitus Other chronic liver disease Previous current hepatocellular carcinoma Use medication know cause steatosis Previous bariatric surgery Pregnancy breastfeed Presence severe medical psychological condition , opinion investigator , would compromise patient 's safe participation include uncontrolled serious psychiatric illness major depression within last 2 year , history severe psychiatric disorder The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>NASH</keyword>
	<keyword>chronic liver disease</keyword>
</DOC>